W hen Ken Tune was preparing yourself to leave his task as the CEO of a little biotech in 2020, he wasn’t sure what was next. However he understood something.
” I intentionally stated I’m not going to do oncology. Oncology is so crowded. Everyone believes they have the service, however the truth is, it’s all sound,” he stated.
That was till late March 2020, when he got 2 call from 2 various financiers, both contemplating about the exact same thing: Was it possible to make more reliable and commonly suitable treatments that drop hazardous radiation particularly to cancer cells, annihilating them on website?
Get unrestricted access to acclaimed journalism and special occasions.